Home / ATYR : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ATYR make money? Does ATYR have pricing power? What's the Earnings Whisper? Will ATYR profit more as the business scales? What is ATYR's management track record? Is ATYR's current price justified?

aTyr Pharma, Inc.

$0.39 -$0.37 (-48.81%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$0.43

Day Range

$0.38$0.42

Year Range

$0.38$1.37

Market Cap

38.1M

AVG Volume

2.11M

Trailing/Forward PE

-0.63/-

PEG ratio

0.25

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

NASDAQ

Revenue (USD)

ATYR Revenue (USD) by year
Period	Revenue (USD)
2025	190K
2024	235K
2023	353K
2022	10.39M
2021	0
2020	10.46M
2019	422K
2018	0
2017	0
2016	0

Net Income (USD)

ATYR Net Income (USD) by year
Period	Net Income (USD)
2025	-74.12M
2024	-64.02M
2023	-50.39M
2022	-45.34M
2021	-33.77M
2020	-16.22M
2019	-23.6M
2018	-34.52M
2017	-48.21M
2016	-57.85M

Operating Income (USD)

ATYR Operating Income (USD) by year
Period	Operating Income (USD)
2025	-77.63M
2024	-67.91M
2023	-54.92M
2022	-46.4M
2021	-34.02M
2020	-15.91M
2019	-22.98M
2018	-32.82M
2017	-47.15M
2016	-57.94M

EBITDA (USD)

ATYR EBITDA (USD) by year
Period	EBITDA (USD)
2025	-72.79M
2024	-62.31M
2023	-47.66M
2022	-43.65M
2021	-32.52M
2020	-14.64M
2019	-21.61M
2018	-32.07M
2017	-46.43M
2016	-57.04M

Cash Flows (USD)

ATYR Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-62.06M
2024	-69.18M
2023	-37.44M
2022	-43.53M
2021	-33.27M
2020	-15.5M
2019	-20.09M
2018	-31.66M
2017	-43.68M
2016	-53.46M

EPS (USD)

ATYR EPS (USD) by year
Period	EPS (USD)
2025	-0.79
2024	-0.87
2023	-0.96
2022	-1.6
2021	-1.88
2020	-1.59
2019	-7.35
2018	-16.14
2017	-26.52
2016	-34.21

Expenses (USD)

ATYR Expenses (USD) by year
Period	Expenses (USD)
2025	77.89M
2024	68.21M
2023	56.75M
2022	57.32M
2021	34.21M
2020	26.57M
2019	23.48M
2018	33.41M
2017	48.46M
2016	58.54M

Cash & Debt (USD)

ATYR Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	78.69M
2024	72.12M
2023	98.17M
2022	66.15M
2021	107.91M
2020	31.69M
2019	31.14M
2018	49.55M
2017	85.12M
2016	72.15M

Debt ratios

ATYR Debt ratios by year
Period	Debt ratios
2025	0.29
2024	0.32
2023	0.6
2022	0.49
2021	1.06
2020	0.26
2019	0.12
2018	0.18

Margins

ATYR Margins by year
Period	Margins
2025	-11547.37%
2024	-5103.4%
2023	-676.49%
2022	89.3%
2020	100%
2019	100%

Return on Capital

ATYR Return on Capital by year
Period	Return on Capital
2025	-110.15%
2024	-91.68%
2023	-55.7%
2022	-63.6%
2021	-30.94%
2020	-51.53%
2019	-112.26%
2018	-102.57%
2017	-75.04%
2016	-92.12%

Shares Outstanding

ATYR Shares Outstanding by year
Period	Shares Outstanding
2025	98.01M
2024	82.72M
2023	59.26M
2022	29.12M
2021	27.79M
2020	10.57M
2019	3.89M
2018	2.17M
2017	2.13M
2016	1.69M

Book Value Per Share (USD)

ATYR Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	0.69
2024	0.84
2023	1.53
2022	2.45
2021	3.93
2020	2.98
2019	5.4
2018	15.53
2017	30.21
2016	37.07

Total Assets (USD)

ATYR Total Assets (USD) by year
Period	Total Assets (USD)
2025	94.16M
2024	96.83M
2023	120.65M
2022	95.79M
2021	115.54M
2020	38.73M
2019	36.19M
2018	52.75M
2017	89.36M
2016	80.52M

Employee Count

ATYR Employee Count by year
Period	Employee Count
2025	56
2024	56
2023	56
2022	65
2021	49
2020	40
2019	39
2018	42
2017	65
2016	58

Free Cash Flow Yield

ATYR Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-143.84%
Sep 26	-130.06%
Sep 26	-112.4%
Aug 26	-103.51%
Aug 26	-111.46%
Aug 26	-100%
Aug 26	-109.3%
Jul 26	-124.52%
Jul 26	-127.79%
Jul 26	-118.64%
Jul 26	-111.1%
Jul 26	-102.08%
Jun 26	-114.66%
Jun 26	-134.25%
Jun 26	-137.33%
Jun 26	-128.68%
May 26	-111.49%
May 26	-123.43%
May 26	-120%
May 26	-66.92%
May 26	-75.97%
Apr 26	-80.66%
Apr 26	-74.2%
Apr 26	-76.07%
Apr 26	-74.77%
Mar 26	-84.21%
Mar 26	-78.34%
Mar 26	-74.5%
Mar 26	-76.85%
Feb 26	-67.55%
Feb 26	-62.34%
Feb 26	-72.53%
Feb 26	-72.12%
Jan 26	-73.45%
Jan 26	-89.67%
Jan 26	-91.5%
Jan 26	-90.98%
Jan 26	-85.42%
Dec 25	-87.29%
Dec 25	-86.45%
Dec 25	-83.61%
Dec 25	-78.7%
Nov 25	-83.07%
Nov 25	-97.58%
Nov 25	-86.08%
Nov 25	-79.37%
Oct 25	-71.31%
Oct 25	-63.95%
Oct 25	-60.54%
Oct 25	-58.26%
Oct 25	-79.66%
Sep 25	-73.47%
Sep 25	-62.25%
Sep 25	-10.24%
Sep 25	-11.01%
Aug 25	-11.48%
Aug 25	-11.54%
Aug 25	-12.6%
Aug 25	-11.65%
Aug 25	-15.3%
Jul 25	-12.34%
Jul 25	-12.01%
Jul 25	-13.57%
Jul 25	-13.55%
Jun 25	-14.3%
Jun 25	-13.78%
Jun 25	-13.83%
Jun 25	-13.37%
May 25	-16.09%
May 25	-19.18%
May 25	-22%
May 25	-21.93%
May 25	-23.23%
Apr 25	-24.96%
Apr 25	-26.98%
Apr 25	-28.16%
Apr 25	-31.92%
Mar 25	-26.72%
Mar 25	-22.73%
Mar 25	-21.07%
Mar 25	-26.04%
Feb 25	-22.36%
Feb 25	-20.49%
Feb 25	-25.96%
Feb 25	-22.7%
Jan 25	-22.93%
Jan 25	-24.66%
Jan 25	-24.52%
Jan 25	-25.08%
Jan 25	-22.24%
Dec 24	-23.67%
Dec 24	-26.43%
Dec 24	-28.93%
Dec 24	-26.35%
Nov 24	-25.08%
Nov 24	-29.22%
Nov 24	-30.42%
Nov 24	-28.37%
Nov 24	-29.15%
Oct 24	-27.26%

Price to Sales

ATYR Price to Sales by year
Period	Price to Sales
Sep 26	200.58
Sep 26	221.84
Sep 26	256.69
Aug 26	278.73
Aug 26	258.85
Aug 26	288.53
Aug 26	263.96
Jul 26	250.63
Jul 26	244.23
Jul 26	263.07
Jul 26	280.92
Jul 26	305.74
Jun 26	272.2
Jun 26	232.47
Jun 26	227.26
Jun 26	242.53
May 26	279.94
May 26	252.85
May 26	260.07
May 26	488.14
May 26	429.95
Apr 26	404.99
Apr 26	440.22
Apr 26	429.39
Apr 26	436.87
Mar 26	387.91
Mar 26	416.96
Mar 26	438.47
Mar 26	425.05
Feb 26	490.78
Feb 26	531.79
Feb 26	457.08
Feb 26	459.69
Jan 26	451.41
Jan 26	369.75
Jan 26	362.33
Jan 26	364.43
Jan 26	388.15
Dec 25	379.82
Dec 25	383.5
Dec 25	396.54
Dec 25	421.29
Nov 25	399.1
Nov 25	339.78
Nov 25	385.14
Nov 25	417.71
May 25	1267.27
Apr 25	1179.27
Apr 25	1091.26
Apr 25	1045.5
Apr 25	922.29
Mar 25	1101.82
Mar 25	1295.43
Mar 25	1397.52
Mar 25	1096.7
Feb 25	1277.34
Feb 25	1393.46
Feb 25	1099.93
Feb 25	1257.99
Jan 25	1245.08
Jan 25	1157.99
Jan 25	1164.44
Jan 25	1138.64
Jan 25	1283.79
Dec 24	1206.38
Dec 24	1080.58
Dec 24	987.03
Dec 24	1083.8
Nov 24	1138.64
Nov 24	977.36
Nov 24	938.65
Nov 24	1006.39
Nov 24	373.72
Oct 24	399.53
Oct 24	367.57
Oct 24	274.14
Oct 24	229.88
Sep 24	217.59
Sep 24	223.74
Sep 24	233.57
Sep 24	231.11
Aug 24	229.88
Aug 24	232.34
Aug 24	234.8
Aug 24	204.54
Aug 24	205.66
Jul 24	249.49
Jul 24	184.31
Jul 24	195.54
Jul 24	169.7
Jun 24	175.32
Jun 24	167.45
Jun 24	205.66
Jun 24	222.52
May 24	194.42

Price to Book

ATYR Price to Book by year
Period	Price to Book
Sep 26	0.78
Sep 26	0.87
Sep 26	1
Aug 26	1.09
Aug 26	1.01
Aug 26	1.13
Aug 26	1.03
Jul 26	0.82
Jul 26	0.8
Jul 26	0.87
Jul 26	0.92
Jul 26	1.01
Jun 26	0.9
Jun 26	0.76
Jun 26	0.75
Jun 26	0.8
May 26	0.92
May 26	0.83
May 26	0.86
May 26	1.38
May 26	1.21
Apr 26	1.14
Apr 26	1.24
Apr 26	1.21
Apr 26	1.23
Mar 26	1.1
Mar 26	1.18
Mar 26	1.24
Mar 26	1.2
Feb 26	1.16
Feb 26	1.26
Feb 26	1.08
Feb 26	1.09
Jan 26	1.07
Jan 26	0.88
Jan 26	0.86
Jan 26	0.87
Jan 26	0.92
Dec 25	0.9
Dec 25	0.91
Dec 25	0.94
Dec 25	1
Nov 25	0.95
Nov 25	0.81
Nov 25	0.91
Nov 25	0.99
Oct 25	1.05
Oct 25	1.17
Oct 25	1.23
Oct 25	1.28
Oct 25	0.94
Sep 25	1.01
Sep 25	1.2
Sep 25	7.28
Sep 25	6.77
Aug 25	6.49
Aug 25	6.46
Aug 25	5.91
Aug 25	6.4
Aug 25	5.43
Jul 25	6.74
Jul 25	6.92
Jul 25	6.12
Jul 25	6.13
Jun 25	5.81
Jun 25	6.03
Jun 25	6.01
Jun 25	6.22
May 25	5.16
May 25	4.33
May 25	3.78
May 25	3.79
May 25	4.26
Apr 25	3.97
Apr 25	3.67
Apr 25	3.52
Apr 25	3.1
Mar 25	3.71
Mar 25	4.36
Mar 25	4.7
Mar 25	3.96
Feb 25	4.61
Feb 25	5.03
Feb 25	3.97
Feb 25	4.54
Jan 25	4.49
Jan 25	4.18
Jan 25	4.2
Jan 25	4.11
Jan 25	4.63
Dec 24	4.35
Dec 24	3.9
Dec 24	3.56
Dec 24	3.91
Nov 24	4.11
Nov 24	3.53
Nov 24	3.39
Nov 24	3.63
Nov 24	2.7
Oct 24	2.89

No video analysis for this stock yet. Request one from our team.

News: ATYR

globenewswire.com · 1 Sep 2026

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

globenewswire.com · 7 Aug 2026

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

globenewswire.com · 15 Jul 2026

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.